Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

NCT03321643 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

NIH

Sponsor class

Conditions

Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Transformed Non-Hodgkin Lymphoma
Richter Syndrome
Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Atezolizumab
PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Biopsy
PROCEDURE: Computed Tomography
DRUG: Gemcitabine
PROCEDURE: Magnetic Resonance Imaging
DRUG: Oxaliplatin
PROCEDURE: Positron Emission Tomography
BIOLOGICAL: Rituximab

Sponsor

National Cancer Institute (NCI)